In a recent development, the Federal Trade Commission (FTC) has issued a policy statement that clarifies its stance on a long-standing concern in the pharmaceutical industry – the improper listing of patents in the Orange Book. The FTC has now confirmed that such mislisting may indeed be considered a violation of the FTC Act. Here is the link to the original announcement.
The policy statement was approved unanimously during a meeting of the commissioners in September. It directly addresses the problem of patents being improperly listed in the Food and Drug Administration’s (FDA) publication of Approved Drug Products with Therapeutic Equivalence.
For those unfamiliar, the Orange Book is a tool utilized by the FDA. It comprises a list of drugs that the agency has approved based on safety and effectiveness. It can influence patent and exclusivity periods, so it’s crucial that its listings are accurate. Mislistings can potentially impact not only the relevant stakeholders, but also public health by delaying the availability of generic drugs.
In conclusion, the new statement serves to remind corporations in the pharmaceutical industry to exercise vigilance when listing patents in the Orange Book. As the Commission’s vote indicates, the FTC is ready to address this issue seriously and take action against potential offenders. This development also underscores the need for pharmaceutical companies to ensure their internal guidelines and practices comply with the law, and the ever-mounting importance of lawful conduct in the health and medical sectors.